Evidence map›Paper›PMID 41869300›Full record

ArticleFrontiers in immunology2026

Long-term outcomes in primary membranous nephropathy: a Chinese cohort study with novel target antigen.

Ping Guo, Wenli Li, Shasha Chen, Xiangyu Yang, Lisha Ma, Changwei Wu, Guisen Li, Wei Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ping GuoSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Wenli LiSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Shasha ChenRenal Department and Nephrology Institute, Sichuan Provincial People's Hospital, Chengdu, China.
Xiangyu YangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Lisha MaSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Changwei WuRenal Department and Nephrology Institute, Sichuan Provincial People's Hospital, Chengdu, China.
Guisen LiSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Wei WangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Long-term antigen-specific data in PMN among Chinese populations remain limited. This study evaluated six target antigens and their clinical significance during extended follow-up. Methods: We retrospectively analyzed 132 treatment-naïve PMN patients diagnosed by biopsy (2010-2018) and followed for a median of 62.9 months. Renal tissue expression of PLA2R, THSD7A, NELL-1, PCDH7, EXT1, and EXT2 was assessed by immunohistochemistry, and serum anti-PLA2R antibodies were measured by ELISA. Associations between antigen profiles and 5-year outcomes (remission, renal survival, malignancy) were evaluated. Results: PLA2R was the predominant antigen (84.1%), followed by THSD7A (5.3%) and NELL-1 (0.76%); no PCDH7, EXT1, or EXT2 positivity was detected. PLA2R-negative patients were more often female (71.4% vs. 36.0%, Conclusions: This >5-year Chinese PMN cohort provides the first comprehensive analysis of six target antigens. PLA2R remains predominant, while PLA2R-negative patients distinct immunopathologic features yet favorable long-term outcomes. A population-specific anti-PLA2R cutoff showed good diagnostic performance for predicting tissue antigen deposition. Rare antigens were infrequent and their malignancy associations require cautious interpretation. These findings provide long-term antigen-specific data supporting antigen-guided, population-adapted precision management of PMN.

Indexed as

AutoantigensGlomerulonephritis, MembranousAdultAutoantibodiesCalcium-Binding ProteinsChinaEast Asian PeopleExostosin 1Exostosin 2FemaleHumansKidneyMaleMiddle AgedN-AcetylglucosaminyltransferasesNerve Tissue ProteinsAutoantibodiesAutoantigensCalcium-Binding ProteinsExostosin 1Exostosin 2N-AcetylglucosaminyltransferasesNELL1 protein, humanNerve Tissue ProteinsPLA2R1 protein, humanReceptors, Phospholipase A2ThrombospondinsTHSD7A protein, humanlong-term outcomesNELL-1PLA2Rprimary membranous nephropathy (PMN)THSD7A

Identifiers

PMID41869300
PMCPMC13002824

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.